Descrizione del progetto
Microscopia innovativa assistita da software per il test della malattia di Lyme
La borreliosi di Lyme è la malattia zoonotica più comune in Europa. Se non viene diagnosticata e trattata precocemente, provoca sintomi gravi e potenzialmente persistenti che rappresentano un pesante onere per il sistema sanitario europeo. Tuttavia, i test sierologici esistenti per la malattia di Lyme sono altamente inaffidabili nelle fasi iniziali. Il reagente e il metodo brevettato DualDur si basano sulla rilevazione diretta dei batteri e non sulla risposta immunitaria, consentendo una diagnosi precoce più affidabile. Si tratta però di un metodo di analisi supplementare svolto presso gli istituti di ricerca. Il progetto DualDur, finanziato dall’UE, convaliderà un’innovativa procedura di analisi basata sulla microscopia assistita da software che migliora di 10 volte il tempo al risultato e richiede meno personale, consentendo così un’applicazione diffusa di DualDur.
Obiettivo
Lyme borreliosis (LB) is the most common zoonotic disease in Europe with 650-850,000 estimated cases. Currently used serological tests for Lyme disease are highly unreliable in early stages of the infection, showing 17-40% sensitivity. If the disease is not diagnosed and treated early on; the infection often spreads to joints, the nervous system, and the heart causing severe and potentially persisting symptoms. Late stage, disseminated LB is a heavy burden on the patients in terms of quality of life and direct and indirect costs. It is also a significant burden on the European healthcare system: the majority of the €1 billion annual cost of the disease is associated with late stage LB. Our patented DualDur reagent and method enables a more reliable early diagnosis of Lyme disease than currently used serological methods, as it is based on direct detection of the bacteria and does not rely on the immune response. So far used as a supplementary testing method mainly at research institutes, in the present project we aim to validate a novel testing procedure based on software-aided microscopy. This will allow the wide-spread application of DualDur, as it improves time-to-result by 10 times, and decreases personnel need compared to our current procedure. Our improved reagent and software-aided testing enables us to provide the DualDur tests all over Europe through partnerships with medical laboratories. More reliable early diagnosis of Lyme disease will reduce the number of later stage cases significantly. This in turn will improve the quality of life of patients and reduce the financial burden of the disease, saving approximately € 330 million on healthcare costs in the first 5 years already. DualDur testing targets the €400 million European Lyme diagnostic market. We will be able to capture 5,1% of this growing market by 2024; representing an annual testing revenue of €23 million at our laboratory partners; and an annual turnover of close to €6 million to our company.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
- natural sciencesbiological sciencesneurobiology
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicineimmunology
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
- medical and health scienceshealth sciencespublic healthepidemiologyzoonosis
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-2-2016-2017
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
2011 BUDAKALASZ
Ungheria
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.